Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers

Clinical Pharmacology in Drug Development

Volumn 3, Issue 3, 2014, Pages 170-178

  Xu, Jianfeng ^a   Gray, Frank ^a   Henderson, Alex ^a   Hicks, Kirsty ^a   Yang, Jiansong ^a   Thompson, Paul ^a   Oliver, Johann ^a  

^a GLAXOSMITHKLINE   (China)

Author keywords

GSK2018682; Pharmacodynamics; Pharmacokinetics; Safety; Sphingosine 1 phosphate receptor agonists

Indexed keywords

4 (4 (5 (5 CHLORO 6 ISOPROPOXYPYRIDIN 3 YL) 1,2,4 OXADIAZOL 3 YL) 1H INDOL 1 YL)BUTANOIC ACID; AGENTS AFFECTING LIPID METABOLISM; FINGOLIMOD; GSK 2018682; PLACEBO; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; GSK2018682; INDOLE DERIVATIVE; OXADIAZOLE DERIVATIVE; S1PR1 PROTEIN, HUMAN;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD SAMPLING; BRADYCARDIA; COHORT ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; EXERCISE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; ADULT; AUSTRALIA; BIOAVAILABILITY; BIOLOGICAL MODEL; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; DRUG FORMULATION; FEMALE; FOOD DRUG INTERACTION; HALF LIFE TIME; HEART RATE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; STATISTICAL MODEL; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; ATRIOVENTRICULAR BLOCK; AUSTRALIA; BIOLOGICAL AVAILABILITY; BRADYCARDIA; CROSS-OVER STUDIES; DRUG COMPOUNDING; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HEALTHY VOLUNTEERS; HEART RATE; HUMANS; INDOLES; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; OXADIAZOLES; RECEPTORS, LYSOSPHINGOLIPID; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84899985217     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.98     Document Type: Article

References (20)

1. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem. 2004; 73:321-354.
2. Im DS, Heise CE, Ancellin N, et al. Charcterization of a novel sphingosine 1-phosphate receptor, Edg-8. J Biol Chem. 2000; 275:14281-14286.
3. Graler MH, Grosse R, Kusch A, Kremmer E, Gudermann T, Lipp M. The sphingosine 1-phosphate receptor S1P4 regulates cell shape and motility via coupling to Gi and G12/13. J Cell Biochem. 2003; 89:507-519.
4. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004; 427:355-360.
5. Wei SH, Rosen H, Matheu MP, et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nature Immunol. 2005; 6:1228-1235.
6. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006; 355:1124-1140.
7. Moberly JB, Rohatagi S, Zahir H, Hsu C, Noveck RJ, Truitt KE. Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phophate receptor-1 modulator. J Clin Pharmacol. 2011; 76:S20-S27.
8. Sanna MG, Liao J, Jo E, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004; 279:13839-13848.
9. Forrest M, Sun SY, Hajdu R, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004; 309:758-768.
10. Hale JJ, Doherty G, Toth L, et al. Selecting against S1P3 enhances the acute cardiovascular tolerability of 3-(N-benzyl)aminopropylphosphonic acid S1P receptor agonists. Bioorg Med Chem Lett. 2004; 14:3501-3505.
11. 1 receptor agonist efficacious at low oral dose and devoid of effects on heart rate. ACS Med Chem Lett. 2011; 2:444-449.
12. Hamada M, Nakamura M, Kiuchi M, et al. Removal of sphingosine 1-phsphate receptor-3 (S1P3) agonism is essential, but inadequate to obtain immunomodulating 1-aminopropane-1, 3-diol S1P1 agonists with reduced effect on heart rate. J Med Chem. 2010; 53:3154-3168.
13. Landeen LK, Dederko DA, Kondo CS, et al. Mechanisms of the negative inotropic effects of sphingosine-1-phosphate on adult mouse ventricular myocytes. Am J Physiol Heart Circ Physiol. 2008; 294:H736-H749.
14. Gergely P, Wallstrom E, Nuesslein-Hildesheim B, et al. Phase I study with selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans. Mult Scler. 2009; 15:S31-S150.
15. Salomone S, Potts EM, Tyndall S, et al. Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null nice and pharmacological tools. Br J Pharmacol. 2008; 153:140-147.
16. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362:387-401.
17. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362:402-415.
18. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007; 22:84-105.
19. Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol. 2004; 57:586-591.
20. Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, Hunt T. Multiple-dose FT Y720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol. 2004; 44:532-537.